Agenus Gets FDA Priority Review of Balstilimab in Cervical Cancer
June 17 2021 - 9:18AM
Dow Jones News
By Colin Kellaher
Agenus Inc. on Thursday said the U.S. Food and Drug
Administration granted priority review to its biologics license
application for balstilimab for the treatment of recurrent or
metastatic cervical cancer.
The Lexington, Mass., clinical-stage immuno-oncology company
said the agency set a target action date of Dec. 16 for the
application, which covers balstilimab in cervical cancer with
disease progression on or after chemotherapy.
The FDA grants priority review to medicines that have the
potential to provide significant improvements in the treatment of a
serious disease, and the designation shortens the review
period.
Agenus said cervical cancer claims the lives of more than
300,000 women around the world each year, adding that current
therapies for recurrent or metastatic cervical cancer are limited
to a small subset of patients with limited benefit.
Shares of Agenus, which closed Wednesday at $5, rose nearly 6%
in premarket trading Thursday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 17, 2021 09:16 ET (13:16 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.